Place of mTOR inhibitors in management of BKV infection after kidney transplantation

Thomas Jouve ^1,2, Lionel Rostaing ^1,2,3,4 * , Paolo Malvezzi ¹

Cited by CrossRef: 23

1- Jouve T, Noble J, Rostaing L, Malvezzi P. An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. Expert Opinion on Drug Safety. 2019;18(4):285 [Crossref]

2- Chiodini B, Guillaume-Gentil P, Vanhomwegen C, Hennaut E, Lolin K, Tram N, Le Moine A, Ismaili K. BK Polyomavirus in Pediatric Renal Transplantation—What We Know and What We Do Not. Biomedicines. 2024;12(5):1093 [Crossref]

3- Gard L, van Doesum W, Niesters H, van Son W, Diepstra A, Stegeman C, Groen H, Riezebos-Brilman A, Sanders J, Toland A. A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients. PLoS ONE. 2017;12(6):e0178801 [Crossref]

4- Jouve T, Noble J, Rostaing L, Malvezzi P. Tailoring tacrolimus therapy in kidney transplantation. Expert Review of Clinical Pharmacology. 2018;11(6):581 [Crossref]

5- DEMİR M, MERHAMETSİZ Ö, UYAR M, SEVMİS M, AKTAS S. Outcomes of mTORi-involving minimized immunosuppression protocols in renal transplantation. 2021;4(1):71 [Crossref]

6- Vela C, Jouve T, Chevallier E, Imerzoukene F, Germi R, Le Marechal M, Truffot A, Fiard G, Janbon B, Giovannini D, Malvezzi P, Rostaing L, Noble J. Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study. JCM. 2022;11(24):7292 [Crossref]

7- Cho A, Park S, Han A, Ha J, Park J, Lee K, Min S. A comparative analysis of clinical outcomes between conversion to mTOR inhibitor and calcineurin inhibitor reduction in managing BK viremia among kidney transplant patients. Sci Rep. 2024;14(1) [Crossref]

8- Wolf S, Lauseker M, Schiergens T, Wirth U, Drefs M, Renz B, Ryll M, Bucher J, Werner J, Guba M, Andrassy J. Infections after kidney transplantation: A comparison of mTOR‐Is and CNIs as basic immunosuppressants. A systematic review and meta‐analysis. Transplant Infectious Dis. 2020;22(3) [Crossref]

9- Malvezzi P, Jouve T, Rostaing L. Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?. EBioMedicine. 2018;34:2 [Crossref]

10- Huh K, Lee J, Ha J, Oh C, Ju M, Kim C, Cho H, Jung C, Lim B, Kim Y. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. 2017;32(8):1415 [Crossref]

11- Rostaing L, Jouve T, Terrec F, Malvezzi P, Noble J. Adverse Drug Events after Kidney Transplantation. JPM. 2023;13(12):1706 [Crossref]

12- Sato N, Shiraki A, Mori K, Sakai K, Tan L, Takemura Y, Okuno Y, Tanabe K, Shiraki K. Everolimus reduces BK polyomavirus infection by suppressing its replication and spread of infection. Antiviral Research. 2022;208:105456 [Crossref]

13- Scadden J, Sharif A, Skordilis K, Borrows R. Polyoma virus nephropathy in kidney transplantation. WJT. 2017;7(6):329 [Crossref]

14- Lopez-Soler R, Patel S, Lyubarova R, Pashkovetsky E, Wang S, Schuster D, Chandolias N, Conti D. Pericardial Effusion Associated With Sirolimus Use After Renal Transplantation: A Single-Center Case Series. Transplantation Proceedings. 2019;51(6):1739 [Crossref]

15- Cherneha M, Korth J, Kaulfuß M, Trilling M, Widera M, Rohn H, Dolff S, Babel N, Hoerning A, Kribben A, Witzke O. Reactivations of Latent Viral Infections Are Associated with an Increased Thr389 p70S6k Phosphorylation in Peripheral Lymphocytes of Renal Transplant Recipients. Viruses. 2021;13(3):424 [Crossref]

16- Mohammad D, Kim D, Baracco R, Kapur G, Jain A. Treatment of BK virus with a stepwise immunosuppression reduction and intravenous immunoglobulin in pediatric kidney transplant. Pediatric Transplantation. 2022;26(4) [Crossref]

17- Favi E, Signorini L, Villani S, Dolci M, Ticozzi R, Basile G, Ferrante P, Ferraresso M, Delbue S. In Vitro Study Evaluating the Effect of Different Immunosuppressive Agents on Human Polyomavirus BK Replication. Transplantation Proceedings. 2022;54(7):2035 [Crossref]

18- Korth J, Verheyen J, Witzke O. BK-Polyomavirus-Reaktivierung nach Nierentransplantation. Nephrologe. 2016;11(6):402 [Crossref]

19- Rohn H, Michita R, Schramm S, Dolff S, Gäckler A, Korth J, Heinemann F, Wilde B, Trilling M, Horn P, Kribben A, Witzke O, Rebmann V. HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant. Cells. 2019;8(8):847 [Crossref]

20- Lee K, Park J, Park H, Kwon Y, Lee J, Kim K, Chung Y, Rhu J, Choi S, Kwon G, Kim H, Kang E, Jung C, Shin E, Kawai T, Kim S, Joh J. Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization. 2020;104(7):1472 [Crossref]

21- Mühlbacher T, Beck R, Nadalin S, Heyne N, Guthoff M. Low‐dose cidofovir and conversion to mTOR‐based immunosuppression in polyomavirus‐associated nephropathy. Transplant Infectious Dis. 2020;22(2) [Crossref]